MyMD Pharmaceuticals (NASDAQ:MYMD) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
This table compares MyMD Pharmaceuticals and Achieve Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Achieve Life Sciences||N/A||-72.16%||-65.77%|
This table compares MyMD Pharmaceuticals and Achieve Life Sciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MyMD Pharmaceuticals||$1.58 million||103.64||-$17.58 million||N/A||N/A|
|Achieve Life Sciences||N/A||N/A||-$14.73 million||($5.42)||-1.60|
Achieve Life Sciences has lower revenue, but higher earnings than MyMD Pharmaceuticals.
Volatility and Risk
MyMD Pharmaceuticals has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Institutional and Insider Ownership
14.0% of MyMD Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.2% of Achieve Life Sciences shares are owned by institutional investors. 0.3% of MyMD Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of current recommendations and price targets for MyMD Pharmaceuticals and Achieve Life Sciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Achieve Life Sciences||0||0||4||0||3.00|
Achieve Life Sciences has a consensus price target of $50.33, suggesting a potential upside of 479.88%. Given Achieve Life Sciences’ higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than MyMD Pharmaceuticals.
Achieve Life Sciences beats MyMD Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
About MyMD Pharmaceuticals
MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.